Table 1.
Patient, disease, and transplant characteristics
| MMRD | HLA-matched UD | ||||
|---|---|---|---|---|---|
| Characteristics | N Eval | N (%) | N Eval | N (%) | P-value |
| Number of patients | 89 | 700 | |||
| Age, median (range), years | 89 | 35 (18-64) | 700 | 43 (18-74) | <0.01 |
| Sex | 89 | 700 | 0.50 | ||
| Male | 50 (56) | 367 (52) | |||
| Female | 39 (44) | 333 (48) | |||
| Donor/Recipient race match | --- | 700 | N/A | ||
| Mismatched | 42 ( 6) | ||||
| Matched | 616 (88) | ||||
| Unknown | 42 ( 6) | ||||
| Karnofsky score prior to transplant | 89 | 700 | 0.29 | ||
| <90 | 24 (27) | 158 (23) | |||
| ≥90 | 60 (67) | 469 (67) | |||
| Unknown | 5 ( 6) | 73 (10) | |||
| Disease | 89 | 700 | 0.66 | ||
| AML | 59 (66) | 480 (69) | |||
| ALL | 30 (34) | 220 (31) | |||
| Disease status | 89 | 700 | 0.26 | ||
| CR1 | 61 (69) | 437 (62) | |||
| CR2 | 28 (31) | 263 (38) | |||
| Cytogenetics - AML | 59 | 480 | 0.63 | ||
| Low | 5 ( 8) | 46 (10) | |||
| Intermediate / high | 40 (68) | 345 (72) | |||
| Unknown | 14 (24) | 89 (19) | |||
| Cytogenetics - ALL | 30 | 220 | <0.01 | ||
| Low | 13 (43) | 40 (18) | |||
| Intermediate / high | 8 (27) | 102 (46) | |||
| Unknown | 9 (30) | 78 (36) | |||
| Graft type | 89 | 700 | 0.35 | ||
| Bone Marrow | 35 (39) | 312 (45) | |||
| Peripheral Blood | 54 (61) | 388 (55) | |||
| Conditioning regimen | 89 | 700 | 0.24 | ||
| Ablative | 73 (82) | 535 (76) | |||
| RIC / Non-myeloablative | 16 (18) | 165 (24) | |||
| Use of ATG in conditioning | 87 | 700 | 0.16 | ||
| No | 72 (83) | 616 (88) | |||
| Yes | 15 (17) | 84 (12) | |||
| GVHD prophylaxis | 89 | 700 | 0.01 | ||
| CSA/FK506±others (no MTX) | 10 (11) | 158 (23) | |||
| CSA/FK506 +MTX | 79 (89) | 542 (77) | |||
| Time from diagnosis to transplantation, months, median (range) |
89 | 7 (2-183) | 699 | 7 (1-171) | 0.12 |
| Donor relationship | 89 | 700 | N/A | ||
| Sibling | 54 (61) | --- | |||
| Parent | 15 (17) | --- | |||
| Child | 13 (15) | --- | |||
| Other relative | 7 ( 8) | --- | |||
| Unrelated | --- | 700 (100) | |||
| HLA Difference | 88 | 700 | |||
| HLA-A | 39 (44) | --- | |||
| HLA-B | 25 (28) | --- | |||
| HLA-DRB1 | 25 (28) | --- | |||
| ABO match | 89 | 700 | <0.01 | ||
| Matched | 51 (57) | 300 (43) | |||
| Minor mismatch | 13 (15) | 183 (26) | |||
| Major mismatch /bi-directional | 19 (21) | 217 (31) | |||
| Unknown | 6 ( 7) | 0 | |||
| Donor/Recipient sex match | 89 | 700 | 0.02 | ||
| Male/Male | 26 (29) | 266 (38) | |||
| Male/Female | 22 (25) | 198 (28) | |||
| Female/Male | 24 (27) | 101 (14) | |||
| Female/Female | 17 (19) | 135 (19) | |||
| CMV match | 89 | 700 | <0.01 | ||
| D−/R− | 20 (22) | 217 (31) | |||
| D−/R+ | 14 (16) | 230 (33) | |||
| D+/R− | 14 (16) | 96 (14) | |||
| D+/R+ | 41 (46) | 141 (20) | |||
| Unknown | 0 | 16 ( 2) | |||
| Donor age, year, median (range) | 88 | 38 (9-71) | 700 | 34 (18-60) | 0.05 |
| Year of transplant | 89 | 700 | <0.01 | ||
| 1995-2000 | 55 (62) | 169 (24) | |||
| 2001-2005 | 34 (38) | 531 (76) | |||
| Median follow-up of survivors (range), months |
37 | 54 (3-135) | 299 | 38 (10-149) | |
| Number of death | 52 | 401 | N/A | ||
| Primary disease | 12 (23) | 145 (36) | |||
| New malignancy | 0 | 3 ( 1) | |||
| GVHD | 9 (17) | 48 (12) | |||
| IPN | 7 (13) | 18 ( 4) | |||
| Infection | 9 (17) | 78 (19) | |||
| Organ failure | 8 (15) | 84 (21) | |||
| Graft Failure | 1 ( 2) | 1 (<1) | |||
| Hemorrhage | 1 ( 2) | 14 ( 3) | |||
| Accidental death | 0 | 2 (<1) | |||
| Unknown | 5 (10) | 8 ( 2) | |||
N=number; HLA=Human leukocyte antigen; Ag=Antigen; AML=Acute myeloid leukemia; ALL=Acute lymphoblastic leukemia; CR=Complete remission; RIC=Reduced intensity conditioning; GVHD=Graft versus host disease; CSA=Cyclosporine; FK506=Tacrolimus; MTX=Methotrexate; CMV=Cytomegalovirus; D/R=Donor/Recipient; IPN=Idiopatic pneumonia.